Komori
Share Issuance and Disposal4576D.Western Therapeutics Institute, Inc.Pharmaceuticals

Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions

In March 2026, 4,750 of the 13th Series of Stock Acquisition Rights were exercised, and 475,000 new shares were issued. The number of unexercised stock acquisition rights at month-end was 9,098.

Worth reading
63In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
475000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Exercise of stock acquisition rights with an exercise price adjustment clause

発行・処分する株式数475,000Shares

475,000 new shares (no treasury shares transferred)

発行済株式総数

Exercise ratio for the month under review: 4.75% (as a percentage of the total number issued) / exercise ratio subject to exercise restrictions: 1.04%

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price in March 2026 was ¥83–¥94. Details of the adjustment clause and the floor were Not disclosed
Number of Stock Acquisition Rights
Total number issued: 100,000 (4,750 exercised; 9,098 unexercised at month-end)
Procedures under the Corporate Code of Conduct
Describes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange Rules on Listing and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
Timing 31 July 2025 / Type Issuance of the 13th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalExercise of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of475,000 new shares (no treasury shares transferred)
Dilution RateExercise ratio for the month under review: 4.75% (as a percentage of the total number issued) / exercise ratio subject to exercise restrictions: 1.04%
Total number of issued shares54,356,712 shares (as of the end of the month preceding the month under review) → Not disclosed
Exercise priceThe exercise price in March 2026 was ¥83–¥94. Details of the adjustment clause and the floor were Not disclosed
Number of Stock Acquisition RightsTotal number issued: 100,000 (4,750 exercised; 9,098 unexercised at month-end)
Procedures under the Corporate Code of ConductDescribes compliance with exercise restrictions under Article 434 of the Tokyo Stock Exchange Rules on Listing and the Japan Securities Dealers Association Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financingTiming 31 July 2025 / Type Issuance of the 13th Series of Stock Acquisition Rights (with Exercise Price Adjustment Clause) through a third-party allotment / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the monthly exercise status of the 13th Series of Stock Acquisition Rights in March 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Monthly Update on the Exercise Status of the 13th Stock Acquisition Rights with Exercise Price Adjustment Provisions | D.Western Therapeutics Institute, Inc. (4576) timely disclosure | Komori